Addex Therapeutics Ltd (ADXN)
NASDAQ: ADXN · Real-Time Price · USD
7.20
+0.03 (0.42%)
At close: Mar 9, 2026, 4:00 PM EDT
6.70
-0.50 (-6.94%)
After-hours: Mar 9, 2026, 5:10 PM EDT
Addex Therapeutics Revenue
Addex Therapeutics had revenue of 49.60K CHF in the quarter ending September 30, 2025, a decrease of -14.99%. This brings the company's revenue in the last twelve months to 158.54K, down -71.81% year-over-year. In the year 2024, Addex Therapeutics had annual revenue of 410.04K, down -74.64%.
Revenue (ttm)
158.54K CHF
Revenue Growth
-71.81%
P/S Ratio
37.66
Revenue / Employee
79,269 CHF
Employees
2
Market Cap
7.49M USD
Revenue Chart
* This company reports financials in CHF.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 410.04K | -1.21M | -74.64% |
| Dec 31, 2023 | 1.62M | 172.23K | 11.92% |
| Dec 31, 2022 | 1.44M | -1.71M | -54.18% |
| Dec 31, 2021 | 3.15M | -725.84K | -18.71% |
| Dec 31, 2020 | 3.88M | 1.05M | 36.89% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Evogene | 8.02M |
| Bolt Biotherapeutics | 5.20M |
| Immuron | 4.99M |
| Kiora Pharmaceuticals | 20.00K |
| Alaunos Therapeutics | 6.00K |
| Pulmatrix | 3.00K |
| Ernexa Therapeutics | 1,000.00 |
ADXN News
- 4 weeks ago - Addex Therapeutics (ADXN) Publishes Promising Research on Anxiety Treatment - GuruFocus
- 2 months ago - Addex Therapeutics (ADXN) Advances NTX-253 into Clinical Trials for Schizophrenia - GuruFocus
- 2 months ago - Addex Spin-Out Neurosterix has started a Phase 1 Clinical Study with M4 PAM - NTX-253 for Schizophrenia - GlobeNewsWire
- 3 months ago - Addex Amends its at the Market Offering Agreement With H.C. Wainwright & Co. - GlobeNewsWire
- 3 months ago - Addex Therapeutics Ltd (ADXN) Q3 2025 Earnings Call Highlights: Strategic Advances Amidst ... - GuruFocus
- 3 months ago - Q3 2025 Addex Therapeutics Ltd Earnings Call Transcript - GuruFocus
- 3 months ago - Addex Therapeutics Ltd (ADXN) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Earnings Scheduled For December 4, 2025 - Benzinga